the sunless-tan peptide that never got approved
1980s–1990s (compound conceived early-to-mid 1980s; self-experimentation and the sexual-effects pivot documented 1989–1998; Hadley's own peer-reviewed first-person account published 2005)
Melanotan II was built to give pale, burn-prone skin a tan without the sun — it never got approved as a tanning drug, but two of its molecular offspring did: one now treats a rare light-sensitivity disorder, the other treats low sexual desire in women.
Melanotan II started life as something almost wholesome: a skin-cancer prevention project. In the early 1980s at the University of Arizona, chemist Victor Hruby and pigment biologist Mac Hadley set out to build a better version of alpha-melanocyte-stimulating hormone (alpha-MSH) — the body's own signal for darkening skin — so that fair, sunburn-prone people could tan without ever stepping into the UV. The catch is that natural alpha-MSH is hopeless as a drug: it falls apart in the bloodstream within minutes. So the team re-engineered it — a 1980 paper in PNAS described an analog roughly 26 times more potent than the real thing, and locking the peptide into a closed ring split the program into two descendants: the linear Melanotan I and the cyclic Melanotan II, the latter around 1,000 times as potent as the natural hormone.
Then came the twist that rewrote the whole story — and, tellingly, it happened twice, independently, in the same lab. Mac Hadley was among the researchers testing the compound on himself (he later called himself a 'human pincushion'); one day he accidentally injected roughly double his intended dose and, by his own account, experienced an unrelenting erection lasting about eight hours, along with nausea and vomiting — a first-person report he published decades later in Peptides (2005). Separately, Arizona dermatologist Norman Levine, who ran the era's formal dosing trials, noted that one 'very astute' volunteer reported developing spontaneous erections. Two unconnected observers, one very unexpected side effect.
Formal double-blind, placebo-controlled trials led by Hunter Wessells in the late 1990s confirmed it was no fluke: subjects reported erections after 63% of injections, versus 5% on placebo. The university's licensing arm then split the discovery cleanly in two — Melanotan I went to an Australian company, Epitan (later renamed Clinuvel), for the original tanning and photoprotection idea, while Melanotan II's arousal effect was handed to Palatin Technologies, which reworked it into bremelanotide — a subtly altered, carboxylate version — and steered it through full FDA trials as PT-141. A licensing tangle with Competitive Technologies over bremelanotide's rights was settled in 2008, with Palatin keeping the drug and paying $800,000.
Melanotan II itself — the parent compound — was never submitted for approval by anyone. Instead it slipped out of research circles by the mid-2000s and into gyms, tanning salons, and online shops as an unregulated 'tanning injection,' precisely the uncontrolled fate its inventors never intended and couldn't stop once the underlying chemistry became common knowledge.
The core history checks out startlingly well against primary sources — the potency figures, the trial data (63% vs 5%), the $800,000 settlement, and the two FDA-approved descendants are all real and independently corroborated. What's mildly embellished is the tidy single-anecdote version: the sexual side effect actually surfaced twice, independently — in Mac Hadley's own accidental self-overdose and, separately, in a trial patient noticed by Dr. Norman Levine — and the vivid 'eight-hour' detail rests on Hadley's own later account rather than fully independent records.
Melanotan II has never been approved for human use anywhere, and it still circulates as an unregulated 'research chemical' sold online, in gyms, and in tanning salons, usually stamped 'not for human consumption' as a legal fig leaf. It is genuinely uncontrolled in the wild: a 2015 lab analysis found vials labeled 10mg actually held between 4.32 and 8.84mg of peptide, alongside unknown impurities. Regulators from the FDA to the UK's MHRA have warned about it since the late 2000s, and published case reports link it to melanoma and changing moles, dangerously prolonged erections (priapism), muscle breakdown, and kidney and brain complications. Under the 2026 FDA peptide reclassification (effective April 23, 2026) it sits in the tightened Category 2 tier — which so far appears to have pushed buyers further toward gray-market sourcing rather than away from it. The lasting irony: the 'failed tanning drug' actually succeeded twice, through its FDA-approved descendants Scenesse (afamelanotide, for the light-sensitivity disorder erythropoietic protoporphyria) and Vyleesi (bremelanotide, for low sexual desire in women) — just never as a tan, and never under its own name.
